Hormones and Aging: The Endocrine System in Longevity
Hormonal output changes across decades in patterns that differ by axis and by sex. What changes, what it means, and where the longevity evidence points in a direction people find surprising.
The Short Answer
Endocrine output changes with age in axis-specific patterns: sex hormone production falls abruptly in women at menopause and gradually in men from the third decade, growth hormone and IGF-1 decline progressively from early adulthood, DHEA falls steeply from the twenties, thyroid output shifts modestly, and cortisol rhythm flattens. The longevity evidence points in a direction that surprises many people: reduced growth hormone and IGF-1 signalling is associated with longer life in animal models and in some human cohorts, while adequate sex hormone signalling is associated with better function. Hormonal optimisation is therefore not a single direction, and it is the Pillar where clinical management rather than supplementation is most often the appropriate route.
The Axes and How They Change
Gonadal axis
In women, oestradiol and progesterone production falls over the perimenopausal transition and then remains low, a discontinuity with wide-ranging consequences for bone density, vascular function, sleep architecture, thermoregulation, cognition and body composition. In men, total testosterone declines gradually, on the order of one percent per year from the third or fourth decade, while sex hormone binding globulin rises, so free testosterone falls faster than total. Much of the decline in men attributed to age is attributable to adiposity, sleep disruption, alcohol and inactivity, which is a more actionable framing than chronology.
Somatotropic axis
Growth hormone secretion, which occurs in pulses concentrated in deep sleep, declines substantially with age, and IGF-1 falls with it. This is the axis where the longevity literature is counterintuitive: reduced signalling through growth hormone and IGF-1 receptors produces the longest-lived mice known, and human populations with genetic reductions in IGF-1 signalling show favourable metabolic profiles.
Adrenal axis
DHEA and DHEA-S fall steeply from the twenties onward, one of the most consistent endocrine changes with age. Cortisol total output changes modestly, but the diurnal rhythm flattens: the morning peak lowers and evening concentrations rise, which has consequences for sleep, glycaemic control and inflammatory signalling.
Thyroid axis
Thyroid stimulating hormone reference ranges shift upward with age, and mild elevations in older adults have a different significance than in younger ones. Peripheral conversion of T4 to T3 becomes less efficient in the presence of inflammatory load or caloric restriction.
Metabolic hormones
Insulin sensitivity declines, leptin rises with adiposity while leptin sensitivity falls, and adiponectin patterns shift. These are more responsive to body composition and activity than to age itself.
The Growth Signalling Paradox
This is the most important and least discussed tension in hormonal optimisation.
Reduced growth hormone and IGF-1 signalling extends lifespan robustly in mice, and the effect is among the largest known from a single genetic change. Human cohorts with reduced IGF-1 receptor signalling show favourable metabolic markers, and lower IGF-1 in later life associates with lower cancer incidence in several analyses. Meanwhile, growth hormone administration in older adults increases lean mass and reduces fat mass, and does so alongside insulin resistance, fluid retention, joint discomfort and, on the animal evidence, a signalling direction associated with shorter rather than longer life.
So the appearance-and-performance objective and the longevity objective point in opposite directions on this axis. That is not a solvable problem; it is a genuine trade-off that a person has to make knowingly. What can be said is that maximising growth signalling is not a longevity strategy, and anyone presenting it as one is not describing the animal literature.
The reconciliation many people reach in practice is to support the axis indirectly: adequate deep sleep, which is when growth hormone pulses occur, resistance training, which produces local anabolic signalling in muscle without systemic elevation, and sufficient protein, rather than exogenous administration.
Sex Hormones and Function
The picture here is different from the growth axis, and the evidence is more favourable to maintaining signalling.
In women, the loss of oestradiol at menopause accelerates bone loss, changes vascular function, disrupts sleep and affects thermoregulation. Clinical hormone therapy has been through a complete cycle of enthusiasm, alarm and reassessment, and the current position in most specialty guidance is that for women within roughly ten years of menopause onset and without specific contraindications, the balance for symptom management and bone protection is more favourable than the 2000s consensus suggested. This is a clinical decision requiring individual assessment, and it is not a supplement question.
In men, low testosterone associates with reduced muscle mass, bone density, libido, mood and metabolic health. Testosterone therapy is a clinical intervention with genuine benefits in men with consistently low measured values and symptoms, and with considerations including fertility suppression, haematocrit elevation and the need for ongoing monitoring. It is also frequently sought by men whose measured values are normal and whose symptoms are attributable to sleep, adiposity, alcohol or training load, which is where the largest available gains sit.
What supplementation can and cannot do. Correcting inadequate intake of relevant micronutrients supports normal hormone production. Compounds with human evidence for modest effects on testosterone in men, such as ashwagandha, act largely through stress and sleep pathways and produce single-digit to low double-digit percentage changes. No supplement produces effects comparable to clinical hormone therapy, and products implying otherwise are misrepresenting themselves.
The Non-Hormonal Levers That Move Hormones
The most effective interventions in this Pillar are not hormonal.
- Sleep. Testosterone in men falls measurably after a week of restricted sleep in controlled studies. Growth hormone pulses occur in deep sleep. Cortisol rhythm depends on circadian regularity.
- Body composition. Adipose tissue expresses aromatase, converting testosterone to oestradiol, and visceral adiposity is associated with lower testosterone in men and with androgen excess patterns in women. Fat loss changes hormonal profiles measurably.
- Resistance training. Produces local anabolic signalling and improves receptor sensitivity, with more reliable effects on function than on circulating hormone concentrations.
- Alcohol reduction. Alcohol affects testicular function, oestrogen metabolism and sleep architecture simultaneously.
- Energy availability. Chronic under-eating relative to expenditure suppresses gonadal and thyroid axis output in both sexes, which is common in athletic populations and often unrecognised.
- Stress management. Chronic hypothalamic-pituitary-adrenal activation suppresses gonadal signalling.
What Is Worth Testing, and How to Read It
Hormonal testing is easy to do badly. Three principles improve it substantially.
Timing matters. Testosterone is highest in the morning and should be measured before mid-morning. Cortisol requires either a timed morning sample or a diurnal profile, since a single random value is close to meaningless. In premenopausal women, oestradiol and progesterone must be interpreted against cycle day.
Free and bound fractions matter. Total testosterone with sex hormone binding globulin allows free testosterone to be calculated, and total alone can be misleading when binding globulin is high or low.
Single values are weak. Hormones are pulsatile and variable. A borderline result should be repeated before it is interpreted, and a result that conflicts with the clinical picture usually deserves a second measurement rather than a decision.
A reasonable panel for a man includes total testosterone, sex hormone binding globulin, oestradiol, luteinising hormone, follicle stimulating hormone and thyroid markers. For a woman it depends on menopausal status and cycle, which is precisely why this is a clinical rather than a self-service exercise.
Adapting Across Decades
This Pillar changes more than any other over a lifetime, and a protocol built in one decade is frequently wrong in the next.
In the thirties, the leverage is almost entirely behavioural: sleep, body composition, training, alcohol and energy availability. In the forties and fifties, the perimenopausal transition in women and the accumulating decline in free testosterone in men make measurement and, for some, clinical management relevant. In the sixties and beyond, the priorities shift toward preserving muscle and bone, where the hormonal environment is one input among several and resistance training and protein intake become the dominant levers.
Two review triggers are non-negotiable in this Pillar. Any new symptom pattern deserves measurement rather than supplementation, since the same presentation can arise from thyroid, gonadal, adrenal or metabolic origins. And anyone on clinical hormone therapy has an ongoing monitoring requirement that supplementation neither replaces nor informs.
The AEONNN Perspective
Hormonal Optimization and Vitality is Pillar 2, and it is the Pillar where AEONNN's boundary is most explicit. AEONNN provides wellness and longevity guidance and does not diagnose or manage endocrine conditions. Where a member's profile points toward hormonal involvement, the appropriate output is often measurement and clinical referral rather than a stack, and Insight Protocol is built to say so rather than to fill the gap with a supplement.
What the platform can do well is reason about the non-hormonal determinants, which is where most of the available change sits. Sleep, body composition, energy availability, alcohol and training load all move hormonal output measurably, and all four sit in other Pillars. That cross-Pillar structure is the point: a member asking about testosterone frequently has a sleep and adiposity question, and a compound-level answer would miss it entirely.
The growth signalling paradox is also a case where AEONNN presents a trade-off rather than a recommendation. The animal longevity evidence and the body composition objective point in opposite directions on that axis, and a member is entitled to see the tension explicitly rather than to receive a confident answer the evidence does not support.
Pillar Matrix mapping
Hormonal Optimization and Vitality, Metabolic and Cardiovascular Health, Longevity and Biological Age
Database Matrix layers
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Meta / Consensus Layer (JAMA, BMJ, specialty society positions)
- Population Layer (UK Biobank, NHANES)
- Safety Layer (DrugBank, FAERS)
- Mechanistic Layer (KEGG, Reactome, UniProt)
Frequently Asked
Does testosterone always decline with age?
Total testosterone declines gradually, on the order of one percent per year from the third or fourth decade, and free testosterone falls faster because binding globulin rises. A substantial part of the decline is attributable to adiposity, sleep disruption, alcohol and inactivity rather than to age itself.
Why would lower growth hormone be better for longevity?
Reduced growth hormone and IGF-1 signalling produces the longest-lived mice known, and human cohorts with reduced IGF-1 signalling show favourable metabolic profiles. Growth signalling supports tissue building and is not associated with longer life when elevated.
Can supplements raise testosterone meaningfully?
Only modestly. Correcting inadequate micronutrient intake supports normal production, and compounds such as ashwagandha produce single-digit to low double-digit percentage changes largely through stress and sleep pathways. No supplement approaches clinical hormone therapy.
What is the best time to test hormones?
Testosterone before mid-morning, since it peaks early. Cortisol as a timed morning sample or a diurnal profile rather than a random value. In premenopausal women, oestradiol and progesterone interpreted against cycle day.
Is hormone therapy at menopause safe?
Current specialty guidance is more favourable than the consensus of the 2000s for women within roughly ten years of menopause onset without specific contraindications. It is an individual clinical decision requiring assessment, not a general recommendation.
What non-hormonal factors affect hormones most?
Sleep, body composition, energy availability, alcohol intake, resistance training and chronic stress. Testosterone in men falls measurably after a week of restricted sleep, and adipose tissue converts testosterone to oestradiol through aromatase.
Why does DHEA fall so much with age?
Adrenal DHEA and DHEA-S production declines steeply from the twenties, one of the most consistent endocrine changes with age. Whether supplementing it produces benefit in people with normal adrenal function is not well established.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.